Condition: Biochemical Recurrence of Malignant Neoplasm of Prostate · Sponsor: Technical University of Munich
The REFINE study is evaluating whether a fluciclovine (18F) PET/CT scan can detect recurrent prostate cancer in patients whose previous PSMA PET/CT was negative or inconclusive.
This description comes directly from the study's public registry record.
Matthias Eiber, MD · +49 89 4140 0 · matthias.eiber@tum.de
Always discuss trial participation with your own doctor first.
| University Hospital Augsburg | Augsburg, Bavaria, Germany | Not Yet Recruiting |
| TUM University Hospital | Munich, Bavaria, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06859203